DDInter1087 DDInter1676
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lonafarnib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Lonafarnib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Lonafarnib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Lonafarnib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Lonafarnib {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Lonafarnib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Lonafarnib may lead to a major life threatening interaction when taken with Enzalutamide
Lonafarnib may lead to a major life threatening interaction when taken with Halofantrine